Cardiogen (20mg)

Cardiogen Research

Research suggests Cardiogen stimulates cardiac cell proliferation, inhibits fibroblast-driven scar formation, and reduces apoptosis by suppressing p53 protein expression. Investigated for applications in heart disease (e.g., heart failure, myocardial infarction) and tissue regeneration, it may also influence cancer pathways by promoting tumor cell apoptosis in sarcoma models.

Cardiogen’s Dual Mechanism in Cardiac Repair

An experimental study investigated cardiac regeneration mechanisms using Cardiogen, a synthetic tetrapeptide, in comparative analyses with 20 naturally occurring amino acids. In heart tissue cultures from rats aged 3 months (young) and 24 months (old), Cardiogen uniquely activated cardiomyocyte proliferation while suppressing apoptosis markers like p53 protein—effects not observed with individual amino acids. This dual action suggests Cardiogen operates through distinct pathways compared to standard nutrient-based approaches, combining growth stimulation with cell survival mechanisms.

Notably, age-related disparities emerged in responses to conventional amino acids: seven amino acids showed proliferative effects in young rats versus only two in older specimens. Cardiogen’s performance remained robust across both age groups, maintaining its efficacy even in aged tissue where natural regenerative capacity diminishes. These findings position the tetrapeptide as a promising candidate for addressing age-related cardiac dysfunction, particularly in elderly populations where current regenerative therapies often underperform.¹

Cardiogen Modifies Tumor Growth in M-1 Sarcoma

Cardiogen peptide exhibits a tumor-modifying effect on M-1 sarcoma in senescent rats by enhancing apoptosis and inducing hemorrhagic necrosis, leading to dose-dependent inhibition of tumor growth. Cardiogen peptide injections resulted in a higher level of apoptosis in tumor cells compared to the control group, indicating its effectiveness in promoting cell death within the tumor.

The growth of M-1 sarcoma was inhibited in a dose-dependent manner following cardiogen administration. The inhibition of tumor growth was not due to a direct cytostatic effect on the tumor cells. Instead, cardiogen appears to work through a specific mechanism involving the tumor’s vascular network, leading to hemorrhagic necrosis and increased apoptosis.²

Cardiogen and Prostate Fibroblast Function

Short peptides such as T-32, T-38, and cardiogen have been shown to significantly enhance the expression of key signaling factors like CXCL12, WEDC1, and ghrelin in aging prostate fibroblasts. These factors are crucial for fibroblast differentiation and their expression decreases in senescent cultures. 

Findings suggest these peptides could reverse age-related declines in prostate fibroblast function, highlighting their potential for developing therapies to counteract prostate aging.³

References

1. Ni, C., Vv, L., Na, B., Sa, U., Ta, U., IuA, S., & An, Z. (2009). The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Advances in gerontology, 22, 409. https://pubmed.ncbi.nlm.nih.gov/22448367/.
2. Levdik, N., & Knyazkin, I. (2009). Tumor-Modifying Effect of Cardiogen Peptide on M-1 Sarcoma in Senescent Rats. Bulletin of Experimental Biology and Medicine, 148, 433-436. https://doi.org/10.1007/s10517-010-0730-9.
3. Kheifets, O., Poliakova, V., & Kvetnoi, I. (2010). [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging].. Advances in gerontology = Uspekhi gerontologii, 23 1, 68-70 . https://pubmed.ncbi.nlm.nih.gov/20586252/.